Key result
An ongoing RCT tests a New Zealand-adapted Mediterranean diet for reducing metabolic syndrome severity.
Why the study?
Cardiometabolic diseases are highly prevalent in Aotearoa New Zealand, and whether a Mediterranean dietary pattern incorporating New Zealand foods combined with behavior change science improves metabolic health is unknown.
Does a New Zealand-adapted Mediterranean dietary pattern with behavior change support improve the metabolic syndrome severity score in adults with metabolic risk and their household members?
RCT (n=200)
Single-blind
Block randomized
Yes
Does a New Zealand-adapted Mediterranean dietary pattern with behavior change support improve the metabolic syndrome severity score in adults with metabolic risk and their household members?
Answers are grounded in this paper and cite their sources.
This protocol outlines a randomized controlled trial to evaluate the efficacy of a New Zealand-adapted Mediterranean diet and behavior change intervention on metabolic syndrome severity.
Background: Cardiometabolic diseases are highly prevalent in Aotearoa New Zealand. Dietary intake is a modifiable risk factor for such diseases and certain dietary patterns, specifically the Mediterranean diet (MedDiet), are associated with improved metabolic health. This study aims to test whether an intervention including a Mediterranean dietary pattern incorporating high quality New Zealand foods (NZMedDiet pattern) and behavior change science can improve the metabolic health of participants and their household/whānau. Methods and analysis: This is a multi-center, three-stage trial with two parallel group superiority randomized controlled trials (RCTs), and a longitudinal cohort study embedded within the trial design. The first RCT (RCT 1) is a comparison of the NZMedDiet pattern compared to usual diet for 12 weeks. The Behavior Change Wheel was used to select and implement strategies to support participant adherence to the NZMedDiet, such as web-based nutrition education on healthy shopping and cooking. The second (RCT 2) compares online social support to no online social support for 12 weeks, administered to participants immediately following RCT 1. The third stage is a longitudinal cohort study where all participants are followed from the beginning of their start of the active intervention for 12 months in total. The primary outcome measure for each stage is the metabolic syndrome severity score (MetSSS). The duration of enrolment is 12-15 months. The total recruitment target is 200 index participants and their household/whānau members who participate with them, and the primary analyses will be intention to treat on index participants. Discussion: The trial will test whether the NZMedDiet pattern and behavior change support improves the cardiometabolic health of people in Aotearoa New Zealand. Clinical trial registration: https://www.anzctr.org.au/Default.aspx, identifier ACTRN12622000906752 and https://www.isrctn.com/, identifier ISRCTN89011056 (Spirit 2).
No takes yet. Share an insight, caveat, or question.
Lithander et al. (2023) conducted an RCT in Metabolic syndrome (n=200). New Zealand-adapted Mediterranean dietary pattern (NZMedDiet) and behavior change support vs. Usual dietary intake and lifestyle was evaluated on Metabolic syndrome severity score (MetSSS). A New Zealand-adapted Mediterranean dietary pattern with behavior change support is being evaluated in a randomized controlled trial to determine its effect on the metabolic syndrome severity score.
Synapse has enriched 10 related papers. Consider them for comparative context: